Cargando…
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
Accumulating evidence suggests that the non-receptor tyrosine kinase c-Abl plays an important role in the progression of Parkinson’s disease (PD) and c-Abl inhibition could be neuroprotective in PD and related α-synucleinopathies. Nilotinib, a c-Abl inhibitor, has shown improved motor and cognitive...
Autores principales: | Lee, Saebom, Kim, Sangjune, Park, Yong Joo, Yun, Seung Pil, Kwon, Seung-Hwan, Kim, Donghoon, Kim, Dong Yeon, Shin, Jae Soo, Cho, Dae Jin, Lee, Gong Yeal, Ju, Hyun Soo, Yun, Hyo Jung, Park, Jae Hong, Kim, Wonjoong Richard, Jung, Eun Ah, Lee, Seulki, Ko, Han Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005030/ https://www.ncbi.nlm.nih.gov/pubmed/29897434 http://dx.doi.org/10.1093/hmg/ddy143 |
Ejemplares similares
-
Radotinib attenuates TGFβ -mediated pulmonary fibrosis in vitro and in vivo: exploring the potential of drug repurposing
por: Baek, Suji, et al.
Publicado: (2022) -
Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease
por: Choi, Yeong-Gon, et al.
Publicado: (2023) -
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021) -
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
por: Yun, Seung Pil, et al.
Publicado: (2018) -
Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)